pharmaceutical investing NervGen Pharma Completes $10 Million Initial Public Offering; Shares to Commence Trading on TSX-V on March 15, 2019 – Symbol “NGEN”
U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia
Questcorp and Riverside Make New Gold Discovery in Initial Drill Results from Luis Hill and Famosa Targets at Union Project, Sonora, Mexico
